Pharma Medical Affairs: 2020 and Beyond

McKinsey & Company

Traditionally, the role of medical affairs has been considered a support function within the pharmaceutical industry. But things are changing, with much of it owed to 3 key factors: the need for industry to clearly demonstrate product value; the evolution of new stakeholders and purchasing decision makers—including patients; and the ongoing demand for increased transparency as the use of and audiences for medical data grow. And all of this feeds into the overarching goal of optimizing patient care.

A report by McKinsey & Company, “Pharma Medical Affairs: 2020 and Beyond,” provides an in-depth analysis of the future of medical affairs and predicts some important changes that need to occur to meet the increased demands described above.

Access the full report below: [mepr-show if=”rule: 4078″]


[mepr-hide if=”rule: 4078″]

[mepr-show if=”loggedin”]

Your subscription has expired. To view this content, please visit your account page to purchase a new subscription.


[mepr-show if=”loggedout”]

Please login or purchase a membership to view this content.




Stay Connected with MAPS

Join MAPS on LinkedIn to further build your professional connections within Medical Affairs through our Company and Group Pages.

Follow us on Twitter and say abreast of MAPS activities and key issues for Medical Affairs professionals.